Edwards Lifesciences (EW) announced the company’s Sapien M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic mitral regurgitation who are deemed unsuitable for surgery or transcatheter edge-to-edge therapy. Leveraging the company’s Sapien technology, the Sapien M3 system is the world’s first approved transcatheter valve replacement therapy using a transfemoral approach to treat MR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $75 from $78 at Truist
- Edwards Lifesciences Hold Rating: Balancing Modest Gains and Market Uncertainty
- Cautious Outlook on Edwards Lifesciences Amidst Evolving Clinical Practices and Market Environment
- Edwards Lifesciences: Hold Rating Amid Market Stability and Growth Opportunities
- Edwards Lifesciences’ Growth Potential Boosted by Favorable NCD and Strategic Initiatives